Predicted Trait | |
Reported Trait | Heart failure |
Mapped Trait(s) | heart failure (EFO_0003144) |
Score Construction | |
PGS Name | PRS12_HF |
Development Method | |
Name | Genome-wide significant SNPs |
Parameters | NR |
Variants | |
Original Genome Build | NR |
Number of Variants | 12 |
Effect Weight Type | beta |
PGS Source | |
PGS Catalog Publication (PGP) ID | PGP000576 |
Citation (link to publication) | Peng H et al. Nutrients (2023) |
Ancestry Distribution | |
Source of Variant Associations (GWAS) | European: 100% 977,323 individuals (100%) |
PGS Evaluation |
Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
---|---|---|---|
GWAS Catalog: GCST009541 Europe PMC: 31919418 |
977,323 individuals | European | NR |
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|
PPM020747 | PSS011390| Multi-ancestry (including European)| 13,348 individuals |
PGP000576 | Peng H et al. Nutrients (2023) |
Reported Trait: Incident heart failure in breast cancer survivors | — | — | Hazard ratio (HR, top 50% vs bottom 50% of PRS): 1.4 [1.06, 1.84] | Age at diagnosis of breast cancer, race, Townsend Deprivation Index, diabetes, hypertension, antihypertensive medications, insulin treatment, lipid treatments, hormone replacement therapy, menopause, surgical treatment of breast cancer, genetic testing batches, 10 PCs | — |
PPM020750 | PSS011390| Multi-ancestry (including European)| 13,348 individuals |
PGP000576 | Peng H et al. Nutrients (2023) |
Reported Trait: Incident heart failure in breast cancer survivors with lifestyle | — | — | Hazard ratio (HR, unhealthy lifestyle and PRS in top 50% vs healthy lifestyle and PRS in bottom 50%): 0.39 [0.21, 0.73] | Age at diagnosis of breast cancer, race, Townsend Deprivation Index, diabetes, hypertension, antihypertensive medications, insulin treatment, lipid treatments, hormone replacement therapy, menopause, surgical treatment of breast cancer, genetic testing batches, 10 PCs | — |
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS011390 | CVD ICD-10: I20-I25, I60-I64, G45 | — | 12,780 individuals, 0.0 % Male samples |
— | European | — | UKB | Mean age of full combined ancestry cohort = 58.8 years (sd = 7.1) |
PSS011390 | CVD ICD-10: I20-I25, I60-I64, G45 | — | 568 individuals, 0.0 % Male samples |
— | Not reported | — | UKB | Mean age of full combined ancestry cohort = 58.8 years (sd = 7.1) |